AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PRIMABioMed announces DCtag antigen collaboration with Institute Pasteur.
2003 JAN 8 - (NewsRx.com & NewsRx.net) -- PRIMABioMed, Ltd., the cancer and immunotherapy research and therapeutic development company, announced that its Panvax, Ltd., subsidiary has entered into a research collaboration with the Paris-based Institute Pasteur to develop the company's DCtag antigen delivery technology in combination with Institute Pasteur's proprietary malaria proteins.
The immediate goal of the collaboration is to assess the potential of the combined technologies as a malaria vaccine.
DCtag is a platform technology with the potential to boost the immune responses to vaccine and immunotherapy products being developed for both human and animal health. PRIMA's Panvax subsidiary is advancing programs in viral diseases and cancer in order to demonstrate that the DCtag technology is able to induce effective immune responses and protection against disease
The collaboration will expand upon previous preclinical results in which DCtag has demonstrated strong protection from malaria infection in mouse models. Panvax's malaria program will be advanced by assessing the potential of a human malaria vaccine to induce effective immune responses to proteins derived from the human malaria parasite ...
- PRIMABioMed Announces Research Collaboration With Institute Pasteur To Develop...
- Press release article from: PR Newswire December 3, 2002 700+ words
...the Paris-based Institute Pasteur to develop the...combination with Institute Pasteur's proprietary...potential to boost the immune responses to vaccine and...induce effective immune responses and protection...
- PRIMABioMed announces DCtag antigen collaboration with Institute Pasteur.
- Newspaper article from: TB & Outbreaks Week January 7, 2003 700+ words
...the Paris-based Institute Pasteur to develop the...combination with Institute Pasteur's proprietary...potential to boost the immune responses to vaccine and...induce effective immune responses and protection...
- New life sciences research from Institute Pasteur described.
- Newspaper article from: Biotech Week January 14, 2009 700+ words
...produce interferon-gamma (IFN-gamma) that primes immune responses. Whereas T helper cell subsets differentiate from naive...protection," wrote N. Satoh-Takayama and colleagues, Institute Pasteur (see also Life Sciences). The researchers concluded...
- Veeco's BioScope II AFM Selected by the Institute Pasteur De Lille.
- Press release article from: Business Wire March 1, 2006 700+ words
...has been selected for purchase by the Institute Pasteur de Lille. The Institute Pasteur de Lille is a private, non-profit...and Pathogenic Infectious Diseases, Institute Pasteur de Lille, stated, "The BioScope II...
- LIGAND PHARMACEUTICALS AND INSTITUTE PASTEUR DE LILLE RESEARCHERS DISCOVER DNA...
- Press release article from: PR Newswire May 28, 1996 700+ words
...Incorporated (Nasdaq: LGND) and the Institute Pasteur de Lille (IPL) reported today that...Staels, Ph.D. of INSERM Unit 325, Institute Pasteur de Lille, has been underway for...international research team that combined the Institute Pasteur's expertise and skills in cell...
- INSTITUTE PASTEUR-KOREA CELEBRATES 1ST ANNIVERSARY.
- News wire article from: AsiaPulse News July 8, 2005 700+ words
SEOUL, July 8 Asia Pulse - Institute Pasteur-Korea, a bioscience research center jointly established by leading institutes of South Korea and France, celebrated its first...
- Institute Pasteur-Korea celebrates 1st anniversary.
- News wire article from: YON - Yonhap News Agency of Korea July 8, 2005 700+ words
SEOUL, July 8 (Yonhap) -- Institute Pasteur-Korea, a bioscience research center jointly established by leading institutes of South Korea and France, celebrated its first...
- Institute Pasteur applies for patent.(Brief Article)
- Newspaper article from: BIOTECH Patent News June 1, 2000 700+ words
Institute Pasteur (Paris, France) has applied for a patent covering cytokine peptides and antibody for preventing and/or treating undesirable immune reactions, e.g. graft rejection and autoimmune disorders. (US Appl. 116594; WO Publication 200004048)
